Optimal management of low-risk gestational trophoblastic neoplasia

References

• Goldstein DP, Berkowitz RS. Current management of gestational trophoblastic neoplasia. HematolOncol Clinics North Amer 2012;26:111-31
   PubMed Web of Science ®Google Scholar
• FIGO Oncology Committee. FIGO staging for gestational trophoblastic neoplasia 2000. IntJ GynaecolObstet 2002;77:285-7
   PubMed Web of Science ®Google Scholar
• Brewer JL, Eckman TR, Dolkart RE, et al. Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J ObstetGynecol 1971;109:335-40
   PubMed Web of Science ®Google Scholar
• Kohorn EI. Negotiating a staging and risk factor scoring system for gestational trophoblastic neoplasia.A progress report. J ReprodMed 2002;47:445-50
   Google Scholar
• Lurain JR. Treatment of gestational trophoblastic disease. Curr Treat Options Oncol 2002;3:113-24
   PubMedGoogle Scholar
• Ngan HY, Seckl MJ. Gestational trophoblastic neoplasia management: An update. CurrOpinOncol 2007;19:486-91
   Google Scholar
• Berkowitz RS, Goldstein DP. Current management of gestational trophoblastic diseases. GynecolOncol 2009;112:654-62
   PubMed Web of Science ®Google Scholar
• Altieri A, Franceschi S, Ferlay J, et al. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003;4:670-8
   PubMed Web of Science ®Google Scholar
• Messerli ML, Lilienfeld AM, Parmley T, et al. Risk factors for gestational trophoblastic neoplasia. AmJObstetGyncol 1985;153:294-300
   PubMed Web of Science ®Google Scholar
• Garrett LA, Garner EO, Feltmate CM, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med 2008;53:481-6
   PubMed Web of Science ®Google Scholar
• Sebire NJ, Foskett M, Fisher RA, et al. Risk of partial and complete molar pregnancy in relation to maternal age. Br J ObstetGynaecol 2002;109:99-102
   PubMed Web of Science ®Google Scholar
• Savage PM, Sita-Lumsden A, Dickson S, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy autcome. J ObstetGynaecol 2013;33:406-11
   Google Scholar
• Elias KM, Goldstein DP, Berkowitz RS. Complete hydatitdform mole in women older than age 50. J Reprod Med 2010;55:208-12
   PubMed Web of Science ®Google Scholar
• Elias KM, Shoni M, Bernstein MR, et al. Complete hydatidiform mole in women aged 40-49 years. J Reprod Med 2012
   PubMed Web of Science ®Google Scholar
• Berkowitz RS, Goldstein DP. Pathogenesis of gestational trophoblastic tumors.Pathobiol Ann. 1981;11:391-411
   Google Scholar
• Cole LA, Kohorn EI. The need for an hCG assay that appropriately detects trophoblastic disease and other hCG-producing tumors. J Reprod Med 2006;51:793-811
   PubMed Web of Science ®Google Scholar
• Cole LA. hCG, its free subunits and its metabolites. Roles in pregnancy and trophoblastic disease. J ReprodMed 1998;43:3-10
   Google Scholar
• Harvey RA, Mitchell HDC, Stenman UH, et al. Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med 2010;285-95
   PubMed Web of Science ®Google Scholar
• Berkowitz RS, Goldstein DP. Clinical practice molar pregnancy. N EnglJ Med 2009;360:1639-45
   PubMed Web of Science ®Google Scholar
• World health organization scientific group on gestational trophoblastic disease. WHO Tech Rep Ser 1983;692:1-80
   Google Scholar
• Agarwal R, Teoh S, Short D, et al. Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study. Lancet 2012;379(9811):130-5
   PubMed Web of Science ®Google Scholar
• Garner EIO, Garrett A, Goldstein DP, Berkowitz RS. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia. J Reprod Med 2004;49:411-14
   PubMed Web of Science ®Google Scholar
• Kohorn EI. Imaging practices in the diagnosis and management of gestational trophoblastic disease. J Reprod Med 2012;57:207-10
   PubMed Web of Science ®Google Scholar
• Hsieh FJ, Wu CC, Chen CE, et al. Correlation of uterine hemodynamics with chemotherapy response in gestational tropoblastic tumors. ObstetGynecol 1994;83:1021-5
   Web of Science ®Google Scholar
• Dhillon T, Palmieri C, Sebire NJ, et al. Value of whole body 18 FDG-PET to identify the active site of gestational trophoblastic neoplasia. J Reprod Med 2006;51:879-87
   PubMed Web of Science ®Google Scholar
• Tse KY, Chan KK, Tam KF, Ngan HY. 20-year experience of managing profuse bleeding in gestational trophoblastic disease. J Reprod Med 2007;52:397-401
   PubMed Web of Science ®Google Scholar
• Alazzam M, Tidy JA, Hancock BW, Osborne R. First line chemotherapy in low risk gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2009;1:CD007102
   PubMed Web of Science ®Google Scholar
• Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database Syst Rev 2012;12:CD008891
   PubMed Web of Science ®Google Scholar
• Sita-Lumsden A, Short D, Lindsay I, et al. Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000-2009. Br J Cancer 2012;197:1810-14
   Web of Science ®Google Scholar
• vanTrommel NE, Massuger LF, Schijf OP, et al. Early identification of resistance to first-line single-agent methotrexate in patients with persistent trophoblastic disease. J ClinOncol 2006;24:52-8
   Web of Science ®Google Scholar
• Agarwal R, Harding V, Short D, et al. Uterine artery pulsatility index: a predicter of methotrexate resistance in gestational trophoblastic neoplasia. Br J Cancer 2012;106:1089-94
   PubMed Web of Science ®Google Scholar
• You B, Harvey R, Henion H, et al. Early prediction of treatment resistance in low-risk gestational trophblastic neoplasia using population kinetic modelling of hCG measurement. Br J Cancer 2013;108:1810-16
   PubMed Web of Science ®Google Scholar
• Yarandi F, Eftekhar Z, Shojaei H, et al. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia. Int J GynaecolObstet 2008;103:33-7
   PubMed Web of Science ®Google Scholar
• Gilani MM, Yarandi F, Eftekhar Z, Hanjani P. Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia. Aust NZ ObstetGynecol 2005;45:161-4
   PubMed Web of Science ®Google Scholar
• Osborne R, Fillaci V, Schink J, et al. Phase III trial of weekly methotrexate versus pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: A Gynecologic Oncology Group Study. J ClinOncol 2011;29:825-31
   PubMed Web of Science ®Google Scholar
• Berkowitz RS, Goldstein DP, Bernstein MR. Ten years’ experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986;23:111-18
   PubMed Web of Science ®Google Scholar
• Khan F, Everard J, Ahmed S, et al. Low-risk gestational trophoblastic disease treated with low-dose methotrexate:efficacy, acute and long-term effects. Br J Cancer 2003;89:2197-201
   PubMed Web of Science ®Google Scholar
• Garrett AP, Garner EIO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. J Reprod Med 2002;47:355-62
   PubMed Web of Science ®Google Scholar
• Homesley HD, Blessing JA, Sclaerth J, et al. Rapid escalation of weekly intrasmuscular methotrexate for non-metastatic gestational trophoblastic disease: A Gynecologic Study Group study. GynecolOncol 1990;305-8
   PubMed Web of Science ®Google Scholar
• Lurain JR. Pharmacotherapy of gestational trophoblastic disease. Expert Opin Pharmacother 2003;43:1-13
   Google Scholar
• Wong LC, Choo YC, Ma HK. Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol 1985;152:59-62
   PubMed Web of Science ®Google Scholar
• Smith EB, Weed JCJr, Tyrey L, et al. Treatment of nonmetastatic gestational trophoblastic disease:results of methotrexate alone versus methotrexate-folinic acid. Am J ObstetGynecol 1982;144:88-92
   PubMed Web of Science ®Google Scholar
• Ross GT, Goldstein DP, Hertz R, et al. Sequential use of methotrexate and actinomycin D in treatment of metastatic choriocarcinoma and related trophoblastic disease in women. Am J ObstetGynecol 1965;93:223-9
   PubMed Web of Science ®Google Scholar
• Schlaerth JB, Morrow CP, Nalick RH, et al. Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. GynecolOncol 1984;19:53-6
   PubMed Web of Science ®Google Scholar
• Hitchins RN, Holden L, Newlands ES, et al. Single agent etoposide in gestational trophoblastic tumours. Experience at charing cross hospital 1978-1987. Eur J Cancer ClinOncol 1988;24:1779-81
   PubMedGoogle Scholar
• Rustin GJS, Newlands ES, Lutz JM, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J ClinOncol 1996;14:2769-73
   PubMed Web of Science ®Google Scholar
• Savage PM, Cook R, O’Nions J, et al. The effects of chemotherapy treatment for gestational trophoblastic tumours on second tumour risk and early menopause. XVII World Con Gest Tro Dis 2014;71-2; Abstract
   Google Scholar
• Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemiaafter etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991;338:359-63
   PubMed Web of Science ®Google Scholar
• Osborne R, Gerulath A. What is the best regimen for low-risk gestational trophoblastic neoplasia? A review. J Reprod Med 2004;49:602-16
   PubMed Web of Science ®Google Scholar
• Lertkhachonsuk A, Israngura N, Wilailak S, et al. Actinomycin D versus methotrexate-folinic acid as treatment for stage I low-risk gestational trophoblastic neoplasia. A randomized controlled trial. Int J Gynecol Cancer 2009;19:985-8
   PubMed Web of Science ®Google Scholar
• Abrao RA, de Andrade JM, Tiezzi DG, et al. Treatment for low-risk gestational trophoblastic disease: comparison of sigle-agent methotrexate, dactinomycin and combination rgimens. Gynecol Oncol 2008;108(1):149-53
   PubMed Web of Science ®Google Scholar
• Soper JT, Clarke-Pearson DL, Berchuck A, et al. 5-day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76-9
   PubMed Web of Science ®Google Scholar
• Roberts JP, Lurain JR. Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J ObstetGynecol 1996;174:1917-23
   PubMed Web of Science ®Google Scholar
• Matsui H, Iitsukla Y, Seki K, Sekiya S. Comparison of chemotherapies with methotrexate, VP-16, and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities. Gynecol Obstet Investig 1998;46:5-8
   PubMed Web of Science ®Google Scholar
• Osathanondh R, Goldstein DP, Pastorfide GB. ActinomycinD as the primaryagent for gestational trophoblastic disease. Cancer 1975;36:863-6
   PubMed Web of Science ®Google Scholar
• Chen LM, Lengyel ER, Bethan Powell C. Single agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. GynecolOncol 2004;94:204-7
   PubMed Web of Science ®Google Scholar
• Lurain JR, Chapman-Davis E, Hoekstra AV, Schink JC. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. J Reprod Med 2012;57:283-7
   PubMed Web of Science ®Google Scholar
• Maesta I, Growdon WB, Goldstein DP, et al. Prognostic factors associated with time to hCG remission in patients with low-risk post-molar gestational trophoblastic neoplasia. GynecolOncol 2013;130:312-16
   PubMed Web of Science ®Google Scholar
• Chapman-Davis E, Hoekstra AV, Rademaker AW, et al. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia:factors associated with resistance to single agent methotrexate chemotherapy. GynecolOncol 2012;125:572-5
   PubMed Web of Science ®Google Scholar
• Shah NT, Barroilhet L, Berkowitz RS, et al. A cost analysis of first-line chemotherapy for low-risk gestational trophoblastic neoplasia. J Reprod Med 2012;57:211-18
   PubMed Web of Science ®Google Scholar
• McNeish IA, Strickland S, Holden L, et al. Low-risk gestational trophoblastic disease:outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J ClinOncol 2002;20:1838-44
   PubMed Web of Science ®Google Scholar
• Mutch DG, Soper JT, Babcock CJ, et al. Recurrent gestational trophoblastic disease. Experience of the Southeastern Regional Trophoblastic Disease Center. Cancer 1990;66:978-82
   PubMed Web of Science ®Google Scholar
• Lybol C, Sweep FC, Harvey R, et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. GynecolOncol 2012;125:576-9
   PubMed Web of Science ®Google Scholar
• McGrath S, Short D, Harvey R. The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100,000 IU/L. Br J Cancer 2010;102:810-14
   PubMed Web of Science ®Google Scholar
• Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. J Reprod Med 2006;51:767-72
   PubMed Web of Science ®Google Scholar
• Pezeshki M, Hancock BW, Silcocks P, et al. The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. GynecolOncol 2004;95:423-9
   PubMed Web of Science ®Google Scholar
• vanTrommel NE, Thomas CM, Massuger LF, Sweep FC. The curative effect of a second curettage in persistent trophoblastic disease;A retrospective cohort study. GynecolOncol 2005;99:6-13
   PubMed Web of Science ®Google Scholar
• Garner EIO, Feltmate CM, Goldstein DP, Berkowitz RS. The curative effect of a second curettage in persistent trophoblastic disease: A retrospective cohort study. GynecolOncol 2005;99:3-5
   PubMed Web of Science ®Google Scholar
• Growdon WB, Wolfberg AJ, Goldstein DP, et al. Evaluation of methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia. GynecolOncol 2009;112:353-7
   PubMed Web of Science ®Google Scholar
• Clark RM, Nevadunsky NS, Ghosh S, et al. The evolving role of hysterectomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2010;55:194-8
   PubMed Web of Science ®Google Scholar
• Matsui H, Iitsuka Y, Suzuka K, et al. Salvage chemotherapy for high –risk gestational trophoblastic tumor. J Repord Med 2004;49:438-42
   PubMed Web of Science ®Google Scholar
• Fleming EL, Garrett L, Growdon WB, et al. The changing role of thoracotomy in gestational trophoblastic neoplasia at the New England Trophoblastic Disease Center. J Reprod Med 2008;53:493-8
   PubMed Web of Science ®Google Scholar
• Yang J, Xiang Y, Wan X, Yang X. The prognosis of gestational trophoblastic neoplasia patients with residual lung tumor after completing chemotherapy.GynecolOncol. 2006;103:479-82
   Google Scholar
• Mapelli P, Mangili G, Picchio M, et al. Role of 18F-FDG-PET in the management of gestational trophoblastic disease.Eur J Nucl Med Mol Imaging. 2013;40:505-13
   Google Scholar
• Sink JD, Hammond CB, Young WG. Pulmonary resection in the management of metastases from choriocarcinoma. J ThoracCardiovascSurg 1981;891:830-5
   Google Scholar
• Lehman E, Gershenson DM, Burke TW, et al. Salvage surgery for chemorefractory gestational trophoblastic disease. J ClinOncol 1994;12:2737-42
   PubMed Web of Science ®Google Scholar
• Ngan HY, Odicino F, Maisonneuve P, et al. Gestational trophoblastic neoplasia. FIGO 26th Annual report on the results of treatment in GyecologicalCancer. Int J GynecolOncol 2006;95(Suppl 1):S193-203
   PubMed Web of Science ®Google Scholar
• Williams J, Short D, Dayal L, et al. The effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia. J Reprod Med 2014;59:248-54
   PubMed Web of Science ®Google Scholar
• Cole LA, Muller CY. HyperglycosylatedhCG in the management of quiescent and chemorefractory gestational trophoblastic diseases. GynecolOncol 2010;116:3-9
   PubMed Web of Science ®Google Scholar
• Kohorn EI. What we know about low-level hCG:definition,classification and management. J Reprod Med 2004;49:433-7
   PubMed Web of Science ®Google Scholar
• Hancock BW. hCG measurement in gestational trophoblastic neoplasia: a critical appraisal. J Reprod Med 2006;51:859-60
   PubMed Web of Science ®Google Scholar
• Vargas R, Barroilhet L, Esselen K, et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia:updated results. J Reprod Med 2014;59:188-94
   PubMed Web of Science ®Google Scholar
• Woolas RP, Bower M, Newlands ES, et al. Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J ObstetGynecol 1998;105:1326-7
   PubMed Web of Science ®Google Scholar
• Blagden SP, Foskett MA, Fisher RA, et al. The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer 2002;86:26-30
   PubMed Web of Science ®Google Scholar
• Cagayan MSFS, Llarena RT. Quality of life of gestational neoplasia survivors: A study of patients at the Philippine General Hospital Trophoblastic Disease Section. J Reprod Med 2010;55:321-6
   PubMed Web of Science ®Google Scholar
• Wenzel L, Berkowitz RS, Newlands ES, et al. Quality of life after chemotherapy for gestational trophoblastic tumor. J Reprod Med 2004;49:531-4
   PubMed Web of Science ®Google Scholar
• Horowitz NS, Wenzel LB. Psychosocial consequences of gestational trophoblastic disease. In: Hancock BW, Seckl MJ, Berkowitz RS, Cole L, Gestational Trophoblastic Disease. 3rd edition. Sheffield, UK: 2009. pp 460-9
   Google Scholar